Phenominer Database Results (22 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 87.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111137 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment thymosin alpha-1 111126 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 21 2.0 x 10E6 cells/ml 0.11 0.51 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111104 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-145 days 15 median 81.7 d 3.87 15.0 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111121 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111138 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 21 1215.0 cells/ul 87.07 399.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111094 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 21 2.1 x 10E6 cells/ml 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111105 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-186 days 21 9.5 % necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111157 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-162 days 15 median 98.7 d 2.17 8.4 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111123 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111130 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-140 days 14 median 77.4 d 6.95 26.0 necropsy 0.0 0 one treatment thymosin alpha-1 111118 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-186 days 21 median 122.6 d 2.42 11.1 necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111145 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 21 81.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111149 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-147 days 14 median 84.0 d 3.61 13.5 necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111122 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111131 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 21 3.39 x 1000 cells/ul 0.16 0.72 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111114 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 21 4.5 x 1000 cells/ul 0.23 1.05 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111115 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 21 9.5 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111153 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 100.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111129 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 111134 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111139 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 21 3664.0 cells/ul 56.74 260.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111095 3196